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A B S T R A C T
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is increasingly used in the treatment of chronic lymphocytic
leukemia (CLL). Moreover, very promising results have been reported in other B-cell malignancies, including
primary central nervous system lymphoma (PCNSL). Although well-tolerated in the majority of patients, ibru-
tinib demonstrates in some cases troublesome toxicities, including invasive fungal infections (IFIs). In the pre-
sent review, we summarize clinical manifestations of IFIs in patients treated with ibrutinib, generally char-
acterized by an early onset, mild clinical manifestations, asymptomatic/low symptomatic pulmonary
localization and high incidence of central nervous system (CNS) involvement. IFI risk appears particularly in-
creased in patients receiving ibrutinib associated with other immune modulator agents, especially with steroids
or immune-chemotherapy. Moreover, the immunomodulatory effect of ibrutinib is described, pointing the at-
tention on the involvement of specific molecules targeted by ibrutinib in innate and adaptive response to fungal
infection. Overall, the findings indicate the ibrutinib may rapidly impair innate immune cell functions, while
concomitantly restoring an effective protective potential of adaptive immune compartment. A correct awareness,
especially when other predisposing factors are present, is warranted about the potential risk of IFIs in ibrutinib-
treated patients.
1. Introduction
Invasive fungal infections (IFIs) are opportunistic diseases that can
occur in hematological malignancies in the presence of multiple pre-
disposing factors. Acute myeloid leukemia (AML) and allogeneic bone
marrow transplantations (alloBMT) are conditions with the highest rate
of IFIs, with an incidence ranging from 5 to 20% in different epide-
miological studies [1–3]. Lymphoproliferative disorders, and in parti-
cular chronic lymphocytic leukemia (CLL), present some features that,
almost in theory, could well correlate with a higher risk of IFIs, simi-
larly to other hematological malignancies. CLL is a disease of elderly,
being 70% of CLL patients older than 65 years, co-morbidities are often
present, especially pulmonary and cardiovascular disorders. More im-
portant, CLL is characterized by a variable grade of immunodeficiency
with enhanced susceptibility to infections. The reason for such higher
susceptibility for infections is considered related to hypogammaglobi-
nemia, T cell depletion and dysfunction, and neutropenia due to bone
marrow involvement and, more frequently, to the effects of immuno-
chemotherapy [4,5]. Moreover, stage, disease status and response to
treatment are additional determinants of infection risk. Nevertheless,
chronic lymphoproliferative disorders are classically considered at low
risk for IFIs [6,7]. In particular, the incidence of IFIs in CLL is con-
sidered low, ranging from 0.5% up to 7.8% [8,9].
In the recent years, new drugs targeting the B-cell receptor signaling
pathway (BCR inhibitors, BCRi) have been introduced in the treatment
algorithm of CLL and of other chronic lymphoproliferative disorders,
demonstrating a high efficacy in relapsed/refractory patients and in
high risk patients with TP53 deletion or mutations [10,11]. These small
molecules were initially considered less immunosuppressive than
chemo-immunotherapy and BCRi were reported, in some cases, to
partially revert the immunosuppressive environment typical of CLL
[12,13]. Patients treated with the Bruton tyrosine kinase inhibitor
(BTKi) ibrutinib in the context of clinical trials have shown moderate
rate of infections, either comparable or inferior to the rate observed in
course of chemo-immunotherapy [14,15]. Nevertheless, the risk of in-
fection remains high even in CLL patients treated with BCRi [16–18].
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Pneumonia is the most common presentation of infection associated
with ibrutinib observed in 4% to 17% of patients [19–21]. The risk of
infections seems to be highest during the first 6months of treatment
and decreases thereafter, probably due to long-term immune recon-
stitution on ibrutinib [22–24]. Recently, Varughese et al. reported the
incidence of serious infections in 378 patients with lymphoid cancer
who received ibrutinib, with 84% of infections occurred during the first
year of treatment and a median time from initiation of ibrutinib of
4.5 months. Serious infections developed in 11.4% of patients. Of these,
37.2% had fungal infections (about 4% of all patients), 53.5% bacterial
infections (about 6% of all patients), mostly Staphylococcus aureus, and
9.3% (about 1% of all patients) viral infections [16]. In the last 2 years,
there is an increasing number of reports describing the occurrence of
unexpected opportunistic fungal infections in ibrutinib-treated patients,
both in single treatment or associated with chemo-immunotherapy or/
and steroids (Tables 1–3).
Ibrutinib inhibits 11 different kinases with an IC50 of about 10 nM
for different Tec kinases as BLK, BMX, CSK, FGR, BRK, HCK, EGFR, YES,
Erb2 and ITK [25]. Further BTK inhibitors (ACP-196/acalabrutinb,
ONO/GS-4059/tirabrutinib, BGB-3111/zanubrutinib) are characterized
by significantly more specificity for BTK than ibrutinib and are cur-
rently evaluated in different clinical trials [10,26–28]. In particular,
acalabrutinib is a potent highly selective BTK inhibitor, currently FDA-
approved for the treatment of mantle cell lymphoma (MCL) and eval-
uated in both relapsed/refractory and treatment-naïve CLL patients,
showing high response rate and durable remissions [28,29]. The rate of
infections varied in different preliminary reports, and one case of fungal
infection after 2months of treatment was reported in phase 1–2 clinical
trials [29–31].
In the present review, we report in a comprehensive manner, bio-
logical and clinical elements that suggest a role of BTK inhibition in the
increased susceptibility to IFIs in patients affected by CLL or other
lymphoproliferative disorders. The first section presents data related to
the clinical incidence of fungal infections in CLL patients treated with
Table 1
Reported cases of invasive aspergillosis in CLL treated with ibrutinib.
Type of IFI HC Site infection Age Prior treatment Concomitant use steroids/
monoclonal
Neutropenia Time after
treatment
Outcome References
IA CLL Lungs brain 76 II No/rituximab NA 2.1months Dead Jain et al. [40]
IA CLL CNS NA Yes (unknown) Yes/no NA 2months Dead Ruchlemer et al. [32]
IA CLL CNS NA Yes (unknown) Yes/no NA 2months Alive Ruchlemer et al. [32]
IA CLL CNS NA Yes (unknown) Yes/no NA 2months Alive Ruchlemer et al. [32]
IA CLL Lungs 62 I No/no No 6weeks Alive Arthurs et al. [39]
IA CLL Sinusitis CNS 75 I No/rituximab No 3weeks Alive Baron et al. [33]
IA CLL CNS 76 IV No/no No 2months Alive Faisal et al. [44]
IA CLL CNS lungs 57 II Yes/no No 1month Alive Periet al. [37]
IA CLL CNS lungs 75 II Yes/no Yes 12 days Alive Gaye et al. [45]
IA CLL CNS lungs 65 No Yes/rituximab No 2months Alive Gaye et al. [45]
IA CLL CNS 66 II No/rituximab No 12months Alive Beresford et al. [46]
IA CLL Lungs 66 III No/no NA 3months Alive Varughese et al. [16]
IA CLL Lungs 72 III No/no NA 10months Alive Varughese et al. [16]
IA CLL Pleural 65 IV No/no NA 3months Alive Varughese et al. [16]
IA CLL CNS lungs 65 V No/ofatumumab NA 7months Alive Varughese et al. [16]
IA CLL Lungs 69 III Yes/no NA 2months Alive Varughese et al. [16]
IA CLL CNS lungs 78 II Yes/no NA 1month Alive Varughese et al. [16]
IA CLL Nasal lesion 34 VII No/no Yes 9months Alive Teh et al. [49]
IA CLL Respiratory tract
vitreus
67 No No/no No 8months Alive Teh et al. [49]
Abbreviations: IFI, invasive fungal infections; IA, invasive aspergillosis; HC, hematological cancer; CLL, chronic lymphocytic leukemia; CNS, central nervous system;
NA, not available.
Table 2
Reported cases of other fungal infections in CLL treated with ibrutinib.
Type of IFI HC Site infection Age Prior treatment Concomitant use steroids/
monoclonal
Neutropenia Time after treatment Outcome References
PJP CLL Lungs 69 No No/no No 1.9months Alive Ahn et al. [59]
PJP CLL Lungs 68 No No/no No 23.6months Alive Ahn et al. [59]
PJP CLL Lungs 72 No No/no No 1.9months Alive Ahn et al. [59]
PJP CLL Lungs 78 II No/no No 6months Alive Ahn et al. [59]
PJP CLL Lungs 70 No No/no No 11.6months Alive Ahn et al.
PJP CLL Lungs 80 II Yes/no Yes 1week Alive [59]
PJP CLL Lungs 68 I No/no NA 20months Alive Kreiniz et al. [43]
M/A CLL Lungs 67 I No/no Yes 7months Dead Kreiniz et al. [43]
M/A CLL CNS, renal spleen 52 I No/no Yes 6months Alive Pouvaret et al. [51]
M CLL Sinuses orbital 79 No NA Yes 17months Alive Serota et al. [34]
M CLL Skin 68 II Yes/no No 3 years Alive Stein et al. [35]
CN CLL CNS 66 IV No/yes No 5months Alive Stankovicz et al. [50]
CN CLL Lungs 73 No Yes/no No 2months Alive Stankovicz et al. [50]
CN CLL Lungs blood 68 I No/no No 1months Alive Okamoto et al. [38]
CN CLL CNS lungs and blood 54 I No/no No 1months Dead Messina et al. [42]
CN CLL CNS, lungs and blood 83 I No/no No NA Alive Abid et al. [36]
CN CLL Lungs 61 II No/no NA 7months Alive Varughese et al. [16]
CN CLL Lungs 70 No No/no NA 5months Alive Varughese et al. [16]
FS CLL Disseminated 46 III No/no Yes 1.5months Alive Chan et al. [41]
Abbreviations: IFI, invasive fungal infections; PJP, Pneumocystis jirovecii pneumonia; M/A, mucormycosis/aspergillosis; M, mucormycosis; CN, Cryptococcus neo-
formans; FS, Fusarium solani; HC; hematological cancer; CLL, chronic lymphocytic leukemia; CNS, central nervous system; NA, not available data.
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ibrutinib. The following section describes the mechanisms of im-
munological defense against fungal infection, pointing the attention on
the role of BTK and ITK molecules. Lastly, the topic of im-
munomodulatory effect of ibrutinib on adaptive and innate immune
activation is also addressed and some clinical recommendations are
included in the last section.
2. Clinical incidence of fungal infections in ibrutinib-treated
patients
An association of ibrutinib treatment with increased risk of fungal
opportunistic infections was initially suggested by several anecdotal
case reports describing the occurrence of IFIs, and in particular invasive
aspergillosis (IA) in ibrutinib-treated CLL patients (Tables 1, 2). Three
cases of cranial aspergillosis have been initially observed in patients
treated with ibrutinib occurring 2months after the initiation of treat-
ment in patients receiving glucocorticoid therapy [32]. Two further
cases of IA and cryptococcal meningoencephalitis (CM) occurring early
in the course of ibrutinib treatment in CLL and Waldenstrom Macro-
globulinemia (WM) patients were described, in absence of classical risk
factors for IFIs, such as neutropenia, lymphopenia, steroid treatment
and HIV infection [33]. Beside these and other reports of sporadic cases
of IA, mucormycosis and cryptococcosis [34–51] (Tables 1, 2), the in-
cidence of opportunistic infections was evaluated in a large cohort of
patients from a single Institution, finding 3% incidence of IFIs in pa-
tients affected by CLL or other lymphoproliferative disorders, treated
with ibrutinib as single agents or combined with chemotherapy or
steroids, with a median follow-up of 2.7 years (range 0.03–6.4) [52].
Similarly, Ruchlemer et al. reported 28 patients with relapsed/re-
fractory CLL or non-Hodgkin lymphoma with IFIs (89% proven, 11%
probable). The median number of prior therapies was 3 and 36% of
patients were concomitantly treated with steroids. Aspergillus fumigatus
(A. fumigatus) was the main pathogen (64% of the cases) and the main
sites of infection were lung (75%) and CNS (brain, sinuses) [53]. In
addition, a retrospective survey aimed at defining cases of IFI among
centers of the French Innovative Leukemia Organization (FILO) CLL
group identified 33 cases, comprising 30 CLL, 1 MCL and 2 WM. All but
one received ibrutinib for relapsed/refractory disease. In this study, the
majority of IFIs were IA (90%, 17 proven, 9 probable and 1 possible),
including 40.7% with CNS involvement. IFI was diagnosed after a
median time from ibrutinib initiation of 3months, and only 2 cases had
a very late-onset of pulmonary aspergillosis (15 and 30months) [54]. In
a study collecting 235 patients (mainly CLL) treated with ibrutinib in 13
hematology centers in Italy, 30% of patients experienced infective
episodes with an incidence of IFIs of 6.4% [55]. Furthermore, in 378
patients with lymphoid cancer (CLL and MCL) who received ibrutinib at
Memorial Sloan Kettering Cancer Center, serious infections developed
in 43 patients (11.4%), primarily during the first year of treatment,
resulting in death in 6/43 (14%) patients. Of these, IFIs occurred in 16
cases (37.2% of cases with serious infections, 4.2% of all patients),
mainly without concomitant classic clinical risk factors for fungal in-
fections (i.e. neutropenia, lymphopenia and use of corticosteroids) [16].
Of relevance, an unexpected high rate of IA was reported in one trial
conducted on patients affected by primary central nervous system
lymphomas (PCNSL) in which ibrutinib was administered in association
with chemotherapy (Table 3). Beside very promising results concerning
efficacy, an extremely high incidence of IA occurred (39% of patients)
[56]. Moreover, a single case of IA also occurred among 13 relapsed/
refractory PCNSL patients treated with ibrutinib as single-agent [57].
Recently, patients with relapsed/refractory PCNSL treated with a
window of ibrutinib for 14 days and then up to 6 cycles of ibrutinib plus
anthracycline-base chemotherapy achieved durable complete remis-
sion, but 2 deaths (15.4%) due to A. fumigatus infection occurred during
ibrutinib window, suggesting that in this setting the use of fungal
prophylaxis and judicious use of steroids may be necessary to reduce
the incidence of fungal infections [58].Ta
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An unexpected high incidence of Pneumocistis jirovecii pneumonia
(PcP) was also reported in CLL patients receiving single-agent ibrutinib.
Five cases out of 96 patients (5.2%) developed PcP, none was on long-
term steroids or other immunosuppressive agents and 4 were previously
untreated, suggesting that ibrutinib per se may confer an increased risk
of pneumocystis infection. Clinical presentation of PcP varied between
asymptomatic and mild dyspnea and cough and symptoms emerged
after a median time of 6months (2–24months) from initiation of
ibrutinib treatment. Moreover, chest computed tomography scan re-
vealed nontypical multifocal nodular infiltrates and in these patients
CD4+ T-cell count was high (> 500 per microliter). All patients re-
solved the infection with early recognition and trimethoprim/sulfa-
methoxazole treatment, without intravenous therapy, adjunctive
steroid treatment or mechanical ventilation [59]. More serious out-
comes of PcP infection were presented by Lee et al. reviewing a series of
PcP cases associated with the use of ibrutinib in patients affected by
CLL, MCL and B-cell lymphoma submitted to the FDA Adverse Event
Reporting System (FAERS). Among 13 patients with ibrutinib-asso-
ciated PcP, 5 deaths were reported [60]. The more favorable outcome
of PcP infection in the former series is probably related to the closer
clinico-laboratory monitoring for early detection of PcP in these pa-
tients, compared to the FAERS cases, possibly reinforcing the advice for
a routine use of trimethoprim/sulfamethoxazole prophylaxis, especially
in patients with additional risk factors of immunosuppression.
Although characterized by an impairment of immune cell functions
due to immunosuppressive action of leukemia cells and further ex-
acerbated by multiple lines of therapy, CLL population is classically
considered at low risk of fungal infections. The emergence of IFIs in
several case reports and in some series of treated patients supports the
notion that ibrutinib may act on the immunological mechanisms im-
plicated into fungal defense, thus increasing risk of fungal infections in
treated patients.
3. Response to fungal infection: focus on ibrutinib “targets”
3.1. BTK-mutated primary immunodeficiency and immune cells
In mice and human, loss of BTK function determines a B-cell dys-
function phenotype with reduced serum immunoglobulin levels and an
increased predisposition to infections. Immunodeficient mice carrying
BTK mutation (Xid) were unable to contain Cryptococcus neoformans
infection in the lung with progressive dissemination to the brain [61].
However, in human, X-linked agammaglobulinemia (XLA) due to BTK
mutations leads to severe immunodeficiency with increased suscept-
ibility to bacterial and enterovirus infections but not to fungal infec-
tions [62,63]. In XLA setting, only one case of opportunistic IFI, in
particular PcP, was reported [64]. Interestingly, in XLA patients, the
functions of dendritic cells (DCs) in terms of T cell stimulation and
expression of costimulatory molecules are not altered in comparison to
healthy controls in response to lipopolysaccharide (LPS)-mediated sti-
mulation of toll-like receptor 4 (TLR4) [65,66]. Accordingly, in Xid
mice, BTK (−/−) DCs exhibit a more mature phenotype and stronger
T-cell stimulatory ability in response to LPS [67]. Although responses to
LPS/TLR4 induce normal DC activation, the CpG/TLR9 pathway is
completely impaired in DCs of patients with XLA [68]. One of docu-
mented clinical features of XLA is neutropenia, that occurs in 11–26%
of cases and is commonly associated with an increase of infectious
episodes [69,70]. In bone marrow samples of XLA patients, signals of
maturation arrest of neutrophils were reported in some cases [70].
Moreover, Xid mice lacking functional BTK showed a reduction in the
number of granulocytic lineages in bone marrow and a deficient
number of neutrophil granulocytes in peripheral blood [71]. In line
with a role of BTK in neutrophil differentiation, Fiedler et al. also de-
monstrated that BTK is important for the expression of lineage-de-
termining transcription factors C/EBPα and PU.1 in granulocyte-
monocyte progenitors (GMP) [72].
3.2. Innate immune cells and BTK
Macrophages and neutrophils are the first line of defense against
human fungal infections, acting mostly throughout phagocytosis and
direct pathogen killing. Of interest, mice with depletion of neutrophils
and monocytes are susceptible to IA [73]. In addition, in primary im-
munodeficiency, IA occurs almost exclusively in patients carrying ge-
netic defects that impair the number and function of phagocytes, im-
plying a pivotal role in fungal defense [74–76]. The prevalence of IA is
particularly high in patients affected by chronic granulomatous disease
(CGD) resulting from a nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex defect in phagocytes that are unable to
generate an efficient reactive oxygen species (ROS) production and
killing of microorganisms [77].
The recognition of fungi by innate immune cells implies interaction
of pathogen-associated molecular patterns (PAMPs, i.e. β-glucans,
chitin and mannans) with multiple pattern recognition receptors
(PRRs), including β-glucan receptor Dectin-1, the CD11b/CD18 (com-
plement receptor 3, CR3), the triggering receptor expressed on myeloid
cells 1 (TREM-1) and Toll-like receptors (TLRs). BTK represents a cru-
cial molecule in the transmission of signaling cascade from all these
immune receptors.
Neutrophils are essential cell type for eliminating A. fumigatus, and
neutropenia remains the primary risk factor for developing IA [78]. The
role of neutrophils is essential in the early stages of fungal infection.
Neutrophil depletion in mice leads to higher mortality prior to or within
3 h after exposition to A. fumigatus conidia, while neutrophil depletion
at later stages of infection is associated with nearly normal survival
rates [79]. Following inflammatory stimuli, neutrophils are recruited to
sites of inflammation to exert the effector functions (Fig. 1A). BTK is
required for E-selectin-mediated slow rolling of neutrophils on inflamed
endothelial cells by activating β2-integrins through PLCγ2 and PI3Kγ
pathways [80]. Accordingly, BTK−/− mice show reduced neutrophil
recruitment into flamed tissue [71]. In addition, the selective reversible
inhibition of BTK, by PRN473, dampens neutrophil influx via inhibition
of adhesion receptor signaling pathways [81]. Recognition of A. fumi-
gatus conidia by neutrophils relies on β-glucan identification by integrin
CR3 which triggers a PI3K-dependent non-oxidative intracellular me-
chanism of killing involving lactoferrin-mediated sequestration of iron.
When conidia escape from early killing and germinate, the extracellular
destruction of Aspergillus hyphae needs opsonization and involves pre-
dominantly recognition via Fcγ receptors, signaling via the spleen tyr-
osine kinase Syk, BTK, PI3K, and protein kinase C to trigger the pro-
duction of toxic reactive oxygen metabolites by the NADPH oxidase and
myeloperoxidase [82]. Neutrophils activate several mechanisms to
control fungal infection, including release of granule proteins and re-
active oxygen species (ROS), phagocytosis of smaller conidia or for-
mation and release of neutrophil extracellular DNA traps (NETs) for
larger hyphae (Fig. 1A) [83]. BTK-deficient neutrophils in mice model
are impaired in expression of several granule proteins [72] and show
poor reactive oxygen intermediates and nitric oxide in response to
different inflammatory stimuli [71].
Macrophages eliminate pathogens by phagocytosis, a process of
internalization followed by degradation. This process initiates by re-
cognition of specific PAMPs by several PRRs (Fig. 1B). One of the main
PRRs involved in anti-fungal immunity is Dectin-1, a C-type lectin that
interacts with fungal β-glucan. Following glucan recognition, the in-
tracellular ITAM-like domain of Dectin-1 is phosphorylated, leading to
the recruitment of Syk. Then, BTK and the guanine nucleotide exchange
factor Vav1 colocalize in the phagocytic cup. In particular, BTK seems
involved in the formation of diacylglycerol (DAG), the recruitment of
PKCε and the activation of calcineurin-NFAT signal [84]. The in-
tracellular cascade generated by Dectin-1 drives actin polymerization
and phagocytosis of fungi as well as cytokine release. Accordingly, BTK-
deficient macrophages show defects in fungal phagocytosis and cannot
generate efficient bursts of ROS [71,85].
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Several TLRs (TLR2, TLR4 and TLR9) are involved in response to
fungal infection, and in particular to A. fumigatus, initiating signaling
and inflammatory cytokine production upon exposure to fungal conidia
spores and hyphae. Absence or inactivation of TLRs leads to an in-
creased risk of fungal infection. In particular, polymorphism Asp229Gly
of TLR4 is associated with increase susceptibility to pulmonary asper-
gillosis and polymorphism T1237C in the promoter of TLR9 is asso-
ciated with allergic bronchopulmonary aspergillosis [86,87]. TLR2 and
TLR4 are membrane bound receptors recruiting TIR domain-containing
adaptor proteins such as MyD88, which initiates signal transduction
pathways that culminate in the activation of NF-κB, IRFs, or MAP ki-
nases (Fig. 1B). TLR2 and TLR4 activation leads to BTK phosphorylation
in macrophages, thus increasing NF-κB signaling as well as TNFα and
IL1β expression upon stabilization of their mRNA throughout p38
MAPK [88]. Crucial activation of calcineurin-NFAT signal occurs via
TLR9-dependent mechanism. Mechanistically, TLR9 is rapidly recruited
to the A. fumigatus-containing phagosomes, then activating BTK which
in turn activates PLCγ2. The PLCγ2 phosphorylation leads to calcium
flux required for calcineurin-mediated NFAT translocation into the
nucleus leading to TNFα production. Inhibition of BTK reduces TNFα
response and NFAT activation [89].
Another mechanism implicated into immune response to fungal
infections is the formation of inflammasome. NLRP3 inflammasome, a
multiprotein complex comprising the NOD-like receptor NLRP3, the
adaptor protein ASC and the proteolytic enzyme caspase-1, mediates
host protection against A. fumigatus by cleavage of IL-1β into its
bioactive form [90]. BTK is a direct regulator of NLRP3 inflammasome,
interacting with ASC and promoting caspase-1 activation [91,92]. Ito
et al. demonstrated that BTK is critically required for NLRP3 in-
flammasome-dependent IL-1β release from murine macrophages in a
brain ischemia/reperfusion in vivo model, by promoting ASC oligo-
merization in a kinase-activity dependent manner [92]. Further studies
are necessary to evaluate the direct role of BTK inhibition on the acti-
vation of NLRP3 inflammasome in response to fungal infection.
TREM-1 belongs to the immunoglobulin-like superfamily of re-
ceptors and is expressed on neutrophils and monocytes. TREM-1 is
coupled to the ITAM-containing adaptor DAP12, leading to Ca2+ mo-
bilization and TNFα and IL-8 secretion [93]. Some studies defined a
role of TREM-1 in the immune response directed against A. fumigatus
[94,95]. In myeloid cells, BTK is implicated in ITAM-mediated TREM-
1/DAP12 signaling, being phosphorylated upon TREM-1 triggering.
After TREM-1 engagement, TNFα production was reduced in PBMCs
from patients with XLA and in bone marrow-derived dendritic cells
(BMDCs) from BTK−/− mice [96].
Dendritic cells (DCs) are antigen presenting cells (APC) responsible
for decoding the fungus-associated information and then for polarizing
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the immune response (Fig. 2). DCs after conidia or hyphae phagocy-
tosis, migrate to the draining lymph nodes, undergo maturation and
produce different cytokines which induce selective priming of CD4+ T
lymphocytes [97]. During pulmonary infections of C. neoformans and A.
fumigatus, the activation of a protective TH1-type response relies on the
presence of monocyte-derived DCs [98,99]. DCs recognize fungi di-
rectly through Dectin-2, dendritic cell-specific intercellular adhesion
molecule 3 grabbing nonintegrin (DC-SIGN) and mannose receptor
(MR), inducing the production of inflammatory cytokines including IL-
1, IL-12 and IL-23, but also IL-4 and IL-10 when in contact with fungal
hyphae. It has been observed that DCs treated with ibrutinib and then
stimulated with LPS show an increase capacity to promote CD4+ T cell
proliferation and IL-17 production [100,101], but an impairment of
TLR9-mediated response is also observed [68].
3.3. Adaptive immune cells and ITK
Although severe and prolonged neutropenia is the most common
risk, invasive fungal infection also occurs in immunocompromised pa-
tients in whom the main immunological deficiency is lymphopenia,
mainly in patients post alloBMT and, less commonly, in AIDS patients
(Fig. 2). In particular, cryptococcosis and PcP are common in patients
with inherited T-cell defects such as idiopathic CD4 lymphopenia and
X-linked CD40 deficiency [102]. During fungal infection, the develop-
ment of an adaptive immunity and the engagement of CD4+ T-cells are
key determinants of the outcome on infection. When T cells encounter a
peptide-loaded APC, the interaction between T cell receptor (TCR) in
cooperation with co-receptors promotes the docking of zeta-associated
protein of 70 kDa (ZAP-70) and activation of the linker for activated T
cells (LAT). This adaptor protein recruits ITK, which phosphorylates
PLCγ1 thus inducing NFAT nuclear translocation and activating NFκB
and MAPK signaling pathways. The relevance of ITK molecule for T cell
function is well defined by the phenotype of ITK knockout mice. ITK−/
− mice showed profound defects in CD4+ T development [103]. In
particular, CD4+ T cells fail to effectively differentiate to TH2 effector
cells, disrupting the ability to mount a protective response to pathogens
such as Listeria monocytogenes. In addition, T cell migration to the lung
and activation are impaired [104]. Moreover, ITK−/− cells fail to
efficiently produce IL-17A, indicating a role of ITK in TH17 differ-
entiation [105]. Of interest, severe viral and opportunistic infections
including PcP were reported in humans with congenital ITK deficiency
[106].
It is largely known that a TH1 response against fungi plays a pro-
tective action against the infection, while a TH2 response characterizes
disease progression [107,108]. TH1 cytokines are mainly represented
by IFN-γ, IL-1 and IL-12, while TH2 response is associated with IL-4 and
IL-10 production [109]. Protective T cells producing IFN-γ, IL-10, IL-4
and IL-17 have been described in patients with IFIs, and in particular in
IA and mucorales infections [110,111]. Activated lymphocytes are able
to bind both A. fumigatus conidia and hyphae, reducing fungal ad-
herence rather than determining a direct fungal damage [112]. Pro-
tective T cells target predominantly aspergillus cell wall antigens, tend
to increase during the infection and are associated with a better clinical
outcome [113]. Throughout the production of IFN-γ, TH1 T cells are
involved in the optimal activation of phagocytes at the site of fungal
infection and promotion of B-cell production of opsonizing antifungal
antibodies. It implies that the failure of T cells to properly deliver ac-
tivating signals to effector innate immune cells may predispose to
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fungal infections. Engineered chimeric antigen receptor T-cells (CAR-T)
modified to recognize β-glucan expressed on the cell wall of fungi are
currently evaluated to defend immunocompromised patients against
life-threating fungal infections, underscoring the relevance of under-
standing the regulation of T-cell response to fungal infection [114,115].
Conversely, TH2 cells dampen protective TH1 response and favor
alternative pathway of macrophage activation (M2), thus are less effi-
cient at controlling fungal growth. Moreover, TH2 cell response to fungi
may be accompanied by a detrimental chronic inflammation and tissue
remodeling [116]. However, TH2 response also exerts a protective ef-
fect against C. neoformans at early stage infection and against P. jir-
ovecii. In addition, the ability of TH2 cells to recruit eosinophils at the
site of infection contributes to A. fumigatus killing after exposure, sug-
gesting that TH2 response may be in some cases beneficial for fungal
clearance [117–119].
TH17 cells have important functions in the host response against
fungal infections, playing a double role in IA. TH17 cells recruit neu-
trophils at the site of infection exerting a protective role against IA, but,
on the other hand, they can promote a chronic inflammatory state with
tissue damage without clearing the infection [120]. In patients with
primary aspergillosis, Aspergillus-specific T cells from the lung showed a
TH17 phenotype [121]. Multiple studies in both humans and mice in-
dicate a role of TH17 cells in protection against candidiasis. IL-17 is
quickly induced upon Candida infection and in turn modulates pro-in-
flammatory cytokines and antimicrobial proteins that protect against
fungal infection [122]. Thus, well-balanced TH1 and TH17-type immune
response against fungi are generally protective and facilitate phagocytic
clearance through the release of IFN-γ, TNF-α, IL-17A and IL-17F, but it
have to be finely regulated to optimize fungal clearance while mini-
mizing tissue damage and recovery tissue homeostasis (Fig. 2). Fur-
thermore, CD25+Foxp3+ T regulatory (Treg) by producing IL-10 have
an anti-inflammatory activity and down-regulate the protective TH1
immune response in course of IA enhancing a TH2 response [123].
4. Immunomodulatory effect of ibrutinib
4.1. Ibrutinib effect on innate immunity
Ibrutinib exerts an immunomodulatory effect, impairing the func-
tions of innate immune cells. Recently, Stadler et al. indicate that BTK
inhibition by ibrutinib affects neutrophil functionality with disruption
of TREM-1 mediated inflammatory response including oxidative burst,
CD62L shedding and CD66b up-regulation. When exposed to A. fumi-
gatus, ibrutinib-treated mice had a higher fungal burden in lungs and
reduced survival compared to untreated-controls [124]. Moreover, an
impaired antibody-dependent cytotoxicity by polymorphonuclear leu-
kocytes (PMNs) treated with ibrutinib was reported [125]. These ob-
servations imply a possible impact of BTK inhibition on neutrophil
functions (Fig. 1).
The ability of macrophages to successfully interact with, engulf,
degrade, present fungal antigens and secrete inflammatory cytokines is
crucial to localize fungal infection in its early stages and to prime the
adaptive immune response. Ibrutinib targets BTK on leukemia-asso-
ciated macrophages (alias, nurse-like cells, NLC) in CLL patients redu-
cing their phagocytic activity and impairing the LPS/TLR4-mediated
STAT1 activation, while allowing IL4-mediated STAT6 phosphoryla-
tion. Ibrutinib-treated NLC also up-regulated M2 markers, i.e. CD163,
IL-10, CD206, NAMPT and CCL18, but decreased TNFα, IL1β and IL2,
suggesting that ibrutinib may exacerbate the skewing of macrophage
population towards an immunosuppressive/tolerogenic phenotype
[126]. Several evidences suggest that BTK contributes to immune-
complex mediated activation of the FcγR signaling pathways in mac-
rophages. Following ibrutinib treatment, FcγR-mediated cytokine re-
lease was suppressed in monocyte population. In particular, ibrutinib
inhibited TNFα, IL-1β and IL-6 production [127–129]. Furthermore,
although ibrutinib does not decrease the viability of macrophages or the
ability of macrophages to bind rituximab-coated CLL cells, it hampered
the phagocytic activity of macrophages towards rituximab- or campath-
opsonized CLL cells [125,130]. In line with these observations, Feng el
al. reported that TLR-mediated phagocytosis of tumor cells by macro-
phages is impaired by ibrutinib treatment, implying a key role of BTK in
the regulation of “eat-me” signal in programmed-cell removal (PrCR)
mechanism [131]. Conversely, Bercusson et al. reported that ibrutinib
impairs fungal growth control by macrophages without affecting their
phagocytic activity [132].
The ability of ibrutinib to impair the macrophage function in treated
CLL patients is uncertain. Niemann et al. observed that in bone marrow
microenvironment ibrutinib disaggregates the interactions between
macrophages and CLL cells, not exerting a direct cytotoxic effect on
macrophages. Moreover, the concentration of the chemokine CXCL13
significantly decreased while CXCL12 increased in bone marrow su-
pernatant obtained from patients on ibrutinib [13]. In line with these
observations, another study found that BTK inhibition in vitro effi-
ciently suppresses production of CXCL12, CXCL13, CCL19, and VEGF
by THP-1 macrophages. BTK inhibitor treatment downregulated se-
cretion of homeostatic chemokines and cytokines through inactivation
of TLR4 signaling and the downstream transcription factors following
LPS stimulation [133]. Recently, Bercusson et al. demonstrated that
ibrutinib is effectively a potent inhibitor of NFAT and NF-κB responses
in human macrophages during infection with A. fumigatus, leading to
reduced secretion of TNFα [132]. Overall, ibrutinib modulates effector
functions of both neutrophils and macrophages. By reducing the ability
of these immune cells to attract and interact with CLL cells, ibrutinib
could favor CLL clearance. But on the other hand, by impairing key
mechanisms of innate immune defense, ibrutinib may increase the risk
of opportunistic infections, potentially decreasing anti-fungal im-
munity, in CLL patients with predisposing conditions.
4.2. Ibrutinib effect on adaptive immune cells
Ibrutinib has multiple immunomodulatory effects on T cell popu-
lation. Dubovsky and colleagues showed that ibrutinib may primarily
suppress the survival of TH2 cells. This effect changed the balance of
TH1/TH2 cells towards TH1 subset both in vitro and in mouse models. In
accordance, serum levels of TH2-type cytokines decreased in ibrutinib-
treated CLL patients [134]. In a comprehensive study of ibrutinib effect
on T cells in treated CLL patients, ibrutinib was reported to increase the
absolute number of CD4 and CD8 T cell populations, not showing the
typical immunosuppressive features of exhausted T cells as indicated by
the reduction in PD-1 and intracellular CTLA-4 expression [12].
Moreover, the number of stem memory T cells was increased, while
Treg cells showed a reduction in percentage among CD4+ population.
Although not observing any signal of T cell polarization towards TH1
profile in CLL patients during ibrutinib treatment, a prompt improve-
ment in the percentage of CD4+ cells secreting IL-17 (TH17) was ob-
served. Overall, the study indicates that ibrutinib enhances the persis-
tence/expansion of activated T cells, probably by sparing chronically
stimulated T cells from activation-induced cell death, and con-
comitantly reduces the number of Treg cells, increases TH17 CD4+
population and reverses the exhausted phenotype of T cell population
[12]. Accordingly, ibrutinib diminished some immunosuppressive fea-
tures of CLL cells, by down-regulating PD-L1, CD200 and IL-10 secre-
tion [12,135]. In other studies, T cell count was reported to decline to
normal levels after 6 and 12months of ibrutinib treatment [13,136]. In
line with this observation, several cytokines related to TH1-, TH2- and
TH17-cell functions decreased in plasma samples of CLL patients, most
of them reaching levels comparable with heathy controls, but others
such as IL-12 and IL-23 becoming hugely different from normal con-
ditions. Interestingly, ibrutinib promotes the recovery of TCR repertoire
diversity after 1 year of treatment, particularly in patients achieving
complete response and with lower rate of infections [136]. Differently
from the study of Long et al., the number of CD4+TH17 T cells was
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reported to decline in ibrutinib-treated CLL patients after 6months due
to ibrutinib ability to inhibit TH17 differentiation and proliferation.
Moreover, a reduction in PD-1 expression was rapidly determined by
ibrutinib on CD3+ T cells [13].
Long-term ibrutinib treatment reversed the proliferative defect and
decreased PD-1 expression on T cells from CLL patients, thus improving
ex vivo CD19-directed CAR-T (CTL019) expansion and in vivo en-
graftment [137]. Accordingly, ibrutinib targeted ITK and promoted an
anti-tumor TH1 phenotype in Vγ9Vδ2-T cells, thus improving T cell
cytotoxicity against CLL cells [138]. All these data clearly indicate the
presence of an immunomodulatory effect of ibrutinib on T cells, by
allowing the reconstitution of effective functions throughout the re-
duction of Treg number and PD-1 expression on T cells while promoting
T cell survival and TH1 expansion. Nevertheless, ibrutinib ameliorates
the progression of chronic graft-versus-host disease (cGVHD) in murine
models and also reduced activation of T and B cells collected from
patients with active cGVHD [139–141]. In 42 patients with cGVHD
treated with ibrutinib, a reduction in absolute number of TH17 and pre-
germinal center B cells, but not in TH1 cells or memory T cells was
observed, depicting the multifactorial activity of ibrutinib on immune
cells [142].
Acalabrutinib (ACP-196) is a second-generation, selective and irre-
versible inhibitor of BTK with absence of targeting at clinically relevant
doses to alternative kinases, such as EGFR, TEC and ITK [143]. Aca-
labrutinib treatment did not change the absolute number of T cells,
natural killer cells and monocytes in relapsed/refractory CLL setting
[12,28], while a decrease of T cell count to normal range after 6months
of treatment was reported in high-risk treatment naïve CLL setting [30].
Of interest, acalabrutinib decreased the PD-1 and CTLA-4 expression on
T cells and IFNγ and TNFα production by CD4+ cells in treated patients
[12]. In Eμ-TCL1 CLL bearing mice, acalabrutinib reduced IL-4, while
increasing IL-2 expression, cytotoxic T cell function and T-cell synapse
area [144], suggesting that second-generation BTK inhibitors may in-
deed influence T cell functions, independently to ITK and its down-
stream targets [145].
5. Conclusion and future directions
The BTK inhibitor ibrutinib is increasingly used in the treatment of
B-cell malignancies. Its use is indicated in CLL, both in first and sub-
sequent lines of treatment, in MCL, in marginal zone lymphoma (MZL)
and WM [146]. Very promising results have been reported in other
lymphoproliferative disorders, including PCNSL [56,57]. Of interest,
ibrutinib was also FDA-approved as second line therapy of steroid-re-
fractory or steroid-resistant cGVHD. It exhibited immunosuppressive
activity in autoimmune disorders and seemed to improve CAR-T en-
graftment and efficacy [137,147].
A higher rate of A. fumigatus infections in patients treated with
ibrutinib was not initially reported in the phase 1–2 and in the sub-
sequent phase 3 trials [19,20]. On the contrary, a higher risk of IFIs
emerged from retrospective clinical experiences in ibrutinib-treated
CLL patients and, especially, in a PCNSL trial, in which ibrutinib was
combined with chemo-immunotherapy and high dose steroids [16,56].
Although the rate of IFIs reported during ibrutinib treatment is not
clearly assessed, it should be considered low. Nevertheless, an increased
risk needs to be highlighted and suspected in patients in which such
infections are considered uncommon, also considering that IFIs occur
unexpectedly even in non-neutropenic ibrutinib-treated patients, sub-
stantially lacking the classical major risk factor for IFIs. IFI risk appears
particularly increased in patients receiving ibrutinib associated with
other immune modulator agents, especially with steroids or immune-
chemotherapy. This finding suggests that ibrutinib impairs fungal im-
mune surveillance and response, a deficit that could be exacerbated by
co-administration of steroids and/or immune-chemotherapy. Notably,
the incidence of IFI among various patient populations receiving ibru-
tinib therapy is different with lower frequencies observed in patients
receiving ibrutinib for WM (the 1 year risk of IA is 0.6%) and for MCL,
highest in patients treated with ibrutinib for CLL and for PCNSL [148].
The reason of these differences is currently unclear, but the specific
composition of tumor microenvironment or the frequencies of con-
comitant risk factors for fungal infections in different patient popula-
tions may be implicated. From a clinical point of view, there are some
aspects that need attention and consideration. Commonly, A. fumigatus
infections arise early during ibrutinib treatment, often during the first
6months of treatment. The reason of this behavior may be related to a
progressive improvement of the adaptive immune functions during
ibrutinib treatment by ITK inhibition in T-lymphocytes [134]. This as-
pect, may, almost partially, counteracts the impairment of innate im-
munity determined by BTK-inhibition in myeloid cells. However, it has
to be considered that some cases of IFIs, in particular PcP and mu-
cormycosis, also occur at later times (Table 2). Reports of larger patient
series with longer follow-up will be useful to define if the increased risk
of fungal infections is maintained or not in patients during long-term
ibrutinib treatment.
A second relevant issue is related to the different and atypical
clinical manifestation of IFIs arising in ibrutinib-treated patients, also
including either mild clinical manifestations or asymptomatic pul-
monary localization. Non-specific pulmonary findings at standard X-ray
or CT scan assays are also present. It should also be noted that the
radiologic diagnosis of IA in non-neutropenic patients is often chal-
lenging. Nodules, with halo sign, revealing angioinvasive aspergillosis
more frequently occurs in neutropenic acute leukemia patients and are
considered required radiologic criteria for a probable diagnosis of IA,
according to EORTC-MSG criteria [149]. Conversely, less well circum-
scribed consolidations without halo signs as well as centrilobular no-
dules and tree-in-bud opacities, revealing airway IA are more fre-
quently detected in non-neutropenic patients, as might be the case of
the majority of non-neutropenic ibrutinib-treated patients with chronic
lymphoproliferative diseases. These latter radiologic findings are rather
unspecific and may frequently be encountered in patients with either
bacterial (i.e. Pseudomonas aeruginosa) or mycobacterial infections. Of
importance, ibrutinib can also cause a drug-related pneumonitis re-
sponsive to prednisone determining organizing pneumonia, interstitial
inflammation or granulomatosis in absence of identifiable micro-
organisms. This non-infectious etiology should be taken into con-
sideration in the differential diagnosis in case of lung infiltrates, mainly
when occurring in the early phase of ibrutinib treatment [150,151].
Thus, microbiologic culture and galactomannan test on bronco-alveolar
lavage are strongly indicated. Trans-bronchial biopsy may also be
considered to guide the most appropriate etiologic therapy of ibrutinib-
treated patients with lung infiltrates [149]. The etiology of severe
pneumonia associated with ibrutinib treatment may, thus, be multi-
factorial, involving preexisting immune-suppression, drug-induced
pneumonitis and infections. The use of steroids to treat a suspected
drug-related toxicity of the lung, may increase the risk of fungal in-
fections in ibrutinib-treated patients. We recommended that physicians
should avoid, or use carefully, concomitant immunosuppressive
therapy and rapidly identify, in case of unexplained fever and dyspnea,
the etiologic origin of the infections in ibrutinib-treated patients in
order to set up the appropriate and safer treatment. Also in the case of
cerebral IA involvement, clinical presentations could be variable and
not typical with meningitis, meningoencephalitis, seizures, or focal
neurological signs related to abscesses. Therefore, watchful and re-
peated neurological examinations are required in patients treated with
ibrutinib showing neurological clinical manifestations, in which a
possible CNS involvement by IFIs should be considered.
Several factors, comprising prolonged neutropenia and CD4+ T cell
lymphopenia, immunosuppressive therapies, systemic inflammatory
diseases, chronic inflammatory diseases, AlloBMT, AIDS and primary
immunodeficiency (CGD), are well-known to be associated with an
increased risk to develop fungal infections. Actually, available clinical
and biological data indicate ibrutinib treatment as a possible additional
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factor favoring the emergence of invasive fungal infections, also in
patients without any other predisposing conditions. The real incidence
of fungal infection in ibrutinib-treated population is currently not well
defined, so further studies on larger cohort of patients may be necessary
to fully understand the entity of additional risk acquired by patients
under ibrutinib therapy. Medical history, social environment and life-
style, the type and stage of hematological malignancy are of importance
in defining individual IFIs risk. Moreover, genetic predisposing factors
may also contribute to individual risk to develop fungal infections
[152]. Actually, fungal prophylaxis cannot be routinely recommended
in ibrutinib-treated patients, either because of the low incidence or
because of interference of antifungal therapy with ibrutinib metabolism
(by inhibiting CYP3A4) with possible increase of adverse events. Given
the relevant drug-drug interaction of strong CYP3A4 inhibitors, like
posaconozole and voriconazole, the dosage of ibrutinib should be re-
duced to 140mg/day, and a careful monitoring of side effects related to
a possible increased ibrutinib exposure is mandatory in patients de-
veloping invasive fungal infections [153,154]. No pharmacokinetic
studies have so far formally addressed whether the use of a moderate
rather than a strong CYP3A4 inhibitor, like isavuconazole, may allow a
lower reduction of ibrutinib dosage. An alternative treatment for fila-
mentous fungi invasive disease could be based on the use of either li-
posomal amphotericin B, which has no effects on ibrutinib metabolism
[155].
Of particular interest is the ability of ibrutinib to control cGVHD
[140,147]. AlloBMT recipients represent one of the categories of pa-
tients at higher risk of developing IFIs [2]. Of importance, many IFIs
may develop when neutrophils counts have been normalized and the
role of cGVHD and immunosuppressive treatments is well documented
[156]. Although at the moment no warning signal was reported using
ibrutinib in cGVHD treatment, attention is required in order to define if
a possible increased risk is really present and clinically caution is ad-
visable during ibrutinib treatment for this subset of patients.
Finally, how ibrutinib decreases fungal immunity is not fully elu-
cidated yet and multiple mechanisms might be involved, including in-
dividual susceptibility together with ibrutinib inhibition of BTK and
other Tec kinases, which are involved in immune response. A correct
awareness, especially when other predisposing factor are present, is
warranted about the potential risk of IFI in ibrutinib-treated patients.
Prospective studies are needed to better assess the effective risk oc-
curring in patients treated with ibrutinib and, not irrelevant, with other
BTK inhibitors.
6. Practice points
• The rate of IFIs during ibrutinib treatment results increased in pa-
tient settings in which opportunistic fungal infections are generally
considered uncommon, although larger studies are warranted to
define the exact frequency of IFI risk in this setting• IFIs, in particular A. fumigatus infections, arise early during ibrutinib
treatment, in general within the first 6months of treatment, and the
use of concomitant immunosuppressive agents (such as steroids or
chemotherapy) may increase the risk of fungal infections, although
vigilance on later occurrence of mold invasive diseases is re-
commended• During ibrutinib treatment, IFIs may arise in non-neutropenic pa-
tients, giving mild and often nonspecific and atypical clinical and
radiological manifestations. The etiology of lung infiltrates should
be promptly investigated and microbiologic culture and galacto-
mannan test on bronco-alveolar lavage are strongly indicated, in
order to obtain a correct differential diagnosis for prompt treatment• Although evaluation of IFIs risk factors (age, genetic predisposition,
environmental exposure, previous and concomitant im-
munosuppressive drug) is of importance for refining individual risk
of fungal infections, fungal prophylaxis cannot routinely be re-
commended
7. Research agenda
• Collaborative studies are needed to accurately define the incidence
of IFIs in larger cohorts of CLL patients treated with BTK inhibitors• The identification of predisposing factors associated with an in-
creased risk of fungal infections in CLL setting is mandatory to select
patients who will benefit from either prophylactic strategies or pre-
emptive/diagnostic-driven therapy approaches.• Improved understanding of mechanisms underlying the reduction of
immune surveillance against fungi in hematological patients treated
with BTK inhibitors is necessary, potentially providing the basis for
experimental immune-based therapies, hopefully targeting not only
adaptive but also innate immunity• Dedicated studies to evaluate fungal infection risk and immune cell
functionality in other settings such as cGVHD patients treated with
ibrutinib are required• The risk of fungal infection needs to be carefully evaluated in the
ongoing trials exploring 2nd generation BTKi, in order to promptly
identify the eventual occurrence of opportunistic infections and in-
vestigate the effect of these BTK-specific inhibitors on T cell function
and monocytes
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